Trial Profile
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Biomarker; Therapeutic Use
- Acronyms LUCINDA
- 01 Aug 2021 Trial design published in the Contemporary Clinical Trials
- 31 Jul 2020 Planned number of patients changed from 180 to 150.
- 31 Jul 2020 Trial design presented at the Alzheimer's Association International Conference 2020